Critical appraisal of ticagrelor in the management of acute coronary syndrome.

With regards to the secondary endpoint of major adverse cardiovascular events (myocardial infarction [MI], death, stroke, severe recurrent ischemia), a favorable trend was seen only with the ticagrelor 180 mg group compared with clopidogrel in terms of fewer MIs at 4 weeks (3.5% versus 1.0%; P = 0.047) and 12 weeks (5.6% versus 2.5%; P = 0.06).

also in 1,335 other papers